Skip to main
TRVI
TRVI logo

TRVI Stock Forecast & Price Target

TRVI Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Trevi Therapeutics has demonstrated a strengthened financial position with a cash balance of $194.9 million, projected to sustain operations through 2028, which positions the company favorably for its late-stage development plans. The company's operational advancements, particularly in progressing Haduvio towards Phase 3 trials for chronic cough indications, reflect meaningful upside potential in an underserved market, with forecasts estimating a $1.5 billion sales opportunity for the drug in idiopathic pulmonary fibrosis alone. Additionally, the narrowing of the net loss to $11.8 million from $13.2 million the previous year underscores improved financial efficiency as clinical momentum continues to build.

Bears say

Trevi Therapeutics Inc. has reported a significant decrease in research and development (R&D) expenses to $10.1 million for Q3, attributed to the winding down of previous clinical trials. The company faces multiple risks including potential delays in the development of its lead product Haduvio, competitive challenges from other therapeutics, and the possibility of losing market exclusivity or facing regulatory hurdles. Additionally, there is an anticipated need for capital raising before reaching profitability, which presents further financial uncertainty and could exacerbate share price volatility.

TRVI has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Trevi Therapeutics Inc (TRVI) Forecast

Analysts have given TRVI a Strong Buy based on their latest research and market trends.

According to 10 analysts, TRVI has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Trevi Therapeutics Inc (TRVI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.